RxDoctor Payments Data

Murtaza Syed, MD

Psychiatry · Winter Park, FLNPI 1972702058

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.5% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Alkermes, Inc. at 52.9% of the total. Reporting peaked in 2019 at $468 and has fallen 94.2% since, to $27 in 2024.

$608in general payments, 2019–2025

Across 9 payments — averaging $67.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$322
  • Johnson & Johnson$116
  • Sage Therapeutics, LLC$94
  • AbbVie$30
  • E.r. Squibb & Sons, L.L.C.$27
  • Supernus Pharmaceuticals, Inc.$19
  • plus $0 from 1 others

What the payments were for

  • Food & beverage$55191%
  • Education$579%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$608 in reported general payments places this provider in the 55th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$57,638
Medicare patients
175
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole41$70,713
Invega SustennaPaliperidone Palmitate17$37,187
VraylarCariprazine Hcl14$23,484
Aripiprazole113$16,967
TrintellixVortioxetine Hydrobromide20$14,185
VyvanseLisdexamfetamine Dimesylate16$7,074
Desvenlafaxine Succinate ErDesvenlafaxine Succinate94$5,438
Duloxetine Hcl143$5,056
Atomoxetine Hcl18$4,023
Ziprasidone Hcl14$3,793
Lisdexamfetamine Dimesylate19$3,420
Venlafaxine Hcl ErVenlafaxine Hcl232$3,352
Quetiapine Fumarate192$3,328
Oxcarbazepine56$2,838
Bupropion XlBupropion Hcl122$2,679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$116$37,18717 claims
AbbVieVraylar$30$23,48414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →